-
SU6656 Src Tyrosine Kinases Inhibitor Guide
2026-08-22
SU6656 is a Src tyrosine kinases inhibitor used in cancer research, platelet biology, and preclinical radiotherapy studies. Available evidence links it to inhibition of PDGF-/Src-driven mitogenesis, megakaryocyte polyploidization, and enhancement of radiation-induced antiangiogenic effects, but the 2026 hiPSC platelet study did not directly validate SU6656 in its optimized protocol.
-
CTOP for μ-Opioid Receptor Signaling Studies
2026-08-21
CTOP enables selective μ-opioid receptor blockade across binding, signaling, tissue, and behavioral assays. This guide translates a 2024 brain-to-spinal circuit study into practical workflows for separating receptor-dependent analgesia, mechanical hypersensitivity, and tolerance.
-
Honokiol for NF-κB and T-Cell Metabolism
2026-08-20
Learn how Honokiol can be integrated into inflammation, oxidative-stress, and CD8+ T-cell immunometabolism workflows without confusing pathway modulation with direct metabolic reprogramming. This practical guide covers compound preparation, assay design, controls, troubleshooting, and hypothesis-driven extensions of a 2024 PKM alternative-splicing study.
-
IAM LC vs LEKC for Pulmonary Permeability
2026-08-20
This 2024 Journal of Chromatography A study provides a direct comparison of immobilised artificial membrane liquid chromatography and liposome electrokinetic capillary chromatography using 26 drug-like molecules. LEKC better reflected apparent pulmonary permeability, whereas IAM LC offered broader compound coverage and simpler high-throughput implementation, defining complementary roles for biomimetic screening.
-
Angiotensin 1/2 (1-6): A Translational RAS Probe
2026-08-19
A mechanistic and strategic guide to using Angiotensin 1/2 (1-6), the Asp-Arg-Val-Tyr-Ile-His hexapeptide, in renin-angiotensin system research, cardiovascular regulation studies, renal function research, and carefully bounded viral-receptor investigations.
-
Fosinopril Sodium Research Workflows
2026-08-19
Build more reproducible hypertension research and cardiovascular disease model workflows with Fosinopril sodium, an ACE inhibitor distinguished by phosphinic acid zinc-ion binding and prodrug activation. Practical guidance covers solution preparation, exposure design, renal hemodynamics modulation, blood pressure reduction, and troubleshooting across in vitro and in vivo studies.
-
Metoprolol Tartrate: Selectivity in Assay Design
2026-08-18
Metoprolol Tartrate is a β1-adrenergic blocking agent for dissecting cardiac signaling while limiting confounding nonselective β-receptor effects. This guide translates transplant-regeneration evidence into practical assay design, formulation, and interpretation decisions.
-
Honokiol at the Immunometabolism–Cancer Interface
2026-08-18
A translational framework for using Honokiol to investigate the intersection of NF-κB signaling, oxidative stress, angiogenesis, and CD8+ T-cell metabolic flexibility without overstating mechanistic evidence.
-
AG-120 (Ivosidenib): Translating IDH1 Biology
2026-08-17
AG-120 (Ivosidenib) offers translational researchers a direct way to interrogate mutant IDH1 biology, from 2-hydroxyglutarate reduction to differentiation. This perspective connects product-level assay design with emerging evidence that CD44-driven metabolic rewiring sustains oncometabolite production in IDH-mutant leukemia, helping researchers design more informative AML studies and resistance experiments.
-
H 89 2HCl in cAMP/PKA Assays
2026-08-17
H 89 2HCl provides a practical way to separate PKA-dependent phosphorylation from upstream cAMP production in neuronal and cell-signaling experiments. This guide translates its biochemical profile into assay workflows for neurite outgrowth, striatal neuron studies, and mechanistic follow-up of the Neuroligin 1–D2-MSN findings.
-
BAY-826 Workflow for Retinal Signaling Studies
2026-08-16
Build more informative retinal neuron-survival assays by pairing BAY-826 pharmacology with Müller cell co-culture, hypoxia, and orthogonal pathway readouts. This guide separates the reported biochemical potency of the compound from cellular-response variables, helping researchers improve dose selection, controls, and troubleshooting.
-
miR-1268a, CD36, and Angiotensin II Heart Failure
2026-08-15
A 2024 study identifies miR-1268a as a regulator of CD36-dependent fatty acid uptake, ATP production, and oxidative stress in Angiotensin II-treated AC16 cardiomyocytes. Its main contribution is a mechanistic link between microRNA dysregulation and metabolic impairment in an in vitro heart failure model, while its findings still require validation in primary cells and animal systems.
-
Biomimetic Chromatography for Lung Permeability
2026-08-14
The reference study evaluates immobilised artificial membrane liquid chromatography and open-tubular capillary electrochromatography, both coupled with mass spectrometry, as biomimetic models of pulmonary drug permeability. Its comparison of 53 structurally diverse compounds shows that IAM-LC provides a useful permeability-related retention model, while OT-CEC-MS adds complementary information about phospholipid composition and drug–membrane interactions.
-
Angiotensin III Workflows for RAAS Research
2026-08-14
Build reproducible RAAS, aldosterone, receptor-signaling, and neuroendocrine assays with Angiotensin III (human, mouse). A practical workflow also explains how recent spike–receptor binding findings can guide carefully controlled cross-domain experiments.
-
Intraperitoneal CAR Macrophage Programming by mRNA-LNP
2026-08-13
Gu and colleagues report a macrophage-targeted mRNA lipid nanoparticle system for programming CAR macrophages directly within the peritoneal cavity. By comparing 36 CAR configurations, single-cell transcriptomics, and checkpoint-blockade combinations, the study identifies CD3ζ–TLR4 intracellular domains as a design that promotes adaptive immune activation while remodeling the immunosuppressive tumor microenvironment.